Skip to main content
Bora Pharmaceuticals Co., Ltd. logo

Bora Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 6472 ISIN · TW0006472004 LEI · 254900MK7O5C2UX1SY03 TW Manufacturing
Open in API
Filings indexed 27 across all filing types
Latest filing 2026-05-12 Regulatory Filings
Country TW Taiwan
Listing TW 6472

About Bora Pharmaceuticals Co., Ltd.

https://bora-corp.com/

Bora Pharmaceuticals Co., Ltd. is a global pharmaceutical service provider that operates through a "dual-engine" business model, integrating comprehensive Contract Development and Manufacturing Organization (CDMO) services with the development and commercialization of specialty pharmaceuticals. The company provides end-to-end solutions ranging from formulation development and clinical trial materials to large-scale commercial manufacturing. Its technical capabilities encompass a diverse array of dosage forms, including oral solids, liquids, and semi-solids. With a manufacturing footprint spanning multiple continents, the company serves global markets by leveraging advanced production technologies and rigorous quality management systems. Bora Pharmaceuticals focuses on strategic growth through acquisitions and partnerships, aiming to enhance manufacturing efficiency and accelerate the delivery of complex therapeutic treatments to patients worldwide.

Recent filings

Filing Released Lang Actions
依「公開發行公司資金貸與及背書保證處理準則」 第二十五條第一項第二及第四款公告申報
Regulatory Filings Classification · 87% confidence The document is an official disclosure by a publicly listed company (Taiwan 6472 保瑞) under the “Procedures for the Handling of Loans by Publicly Issued Companies and Provision of Guarantees”, providing details of guarantees for its subsidiary. It does not contain full financial statements, earnings highlights, or a new report, but is a compliance announcement of a guarantee transaction. This falls under general regulatory filings rather than a specific financial report category.
2026-05-12 Chinese
公告本公司對子公司背書保證餘額達「公開發行公司資金貸與 及背書保證處理準則」第二十五條第一項第一款
Regulatory Filings Classification · 78% confidence The document is a disclosure on the Taiwan ‘公開資訊觀測站’ platform by a listed company (6472 保瑞) announcing that its guarantees for subsidiaries have exceeded 50% of its latest net assets under the “公開發行公司資金貸與及背書保證處理準則.” It is a regulatory compliance announcement detailing guarantee limits and balances, with no substantive financial statements attached. This fits the definition of a general regulatory filing (fallback category).
2026-05-12 Chinese
公告本公司董事會決議對子公司Bora Pharmaceuticals USA Inc.現金增資案
Share Issue/Capital Change Classification · 87% confidence The document is a board resolution announcement (“公告本公司董事會決議對子公司…現金增資案”) detailing the company’s approval to inject US$122.5m in cash to increase the share capital of its wholly‐owned subsidiary. This is an announcement of a share capital change, not a full financial report, earnings release, or dividend notice. It best fits the “Share Issue/Capital Change” category (SHA).
2026-05-12 Chinese
本公司透過新設子公司Bora Biologics USA LLC 取得CDMO營運資產
Regulatory Filings Classification · 85% confidence The document is a public disclosure from the Taiwan ‘公開資訊觀測站’ system by listed company 6472 regarding the acquisition of CDMO operating assets via a new subsidiary. It provides transaction details, board approval, counterparty, pricing, and legal references. This is a generic regulatory announcement of an asset acquisition event and does not fit specialized categories like earnings release, call transcript, M&A takeover bid, or share issuance. Therefore, it falls under the fallback “Regulatory Filings” category.
2026-05-12 Chinese
115年4月背書保證與資金貸與
Regulatory Filings Classification · 76% confidence The document is a short periodic disclosure (c. 654 characters) providing tables on intercompany fund lending balances and endorsement/guarantee information. It does not contain substantive financial statements or constitute an earnings release, annual report, or capital change notice, nor is it a proxy, dividend, or management discussion. It is a routine regulatory disclosure required by the exchange. Thus it falls under the fallback category Regulatory Filings (RNS).
2026-05-11 Chinese
115年4月營業收入
Regulatory Filings Classification · 75% confidence The document is a monthly revenue summary report (“查詢彙總報表”) from the Taiwanese Market Observation Post System (MOPS). It provides actual financial figures (monthly and year‐to‐date revenue comparisons) but is not a full quarterly/interim report, earnings press release, dividend notice, or any other specific filing type. It is part of routine regulatory disclosures and does not neatly fit any other category, so it defaults to a general regulatory filing.
2026-05-11 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.